Vesalio Expands Neurovascular Portfolio with CE, FDA Nod
Plano, Texas — February 10, 2026: Vesalio, a global vascular intervention medical device company, announced major regulatory and commercial...
artificial intelligence ASCO 2026 Autoimmune Disease Bio-Pharma biologics biopharma Biotechnology Cancer Immunotherapy Cancer Research cancer therapy Cell Therapy Clinical Development Clinical Research clinical trial clinical trials Digital Health drug development Eli Lilly FDA fda approval FDA clearance Gene Therapy Healthcare Innovation healthcare technology Immuno-Oncology immunology Immunotherapy Medical Devices MedTech Monoclonal Antibody Neurology NSCLC Oncology oncology innovation Orphan Drug Phase 1 trial Phase 2 Trial Phase 3 trial Precision Medicine Precision Oncology rare disease rare diseases Regenerative Medicine regulatory compliance targeted therapy
Plano, Texas — February 10, 2026: Vesalio, a global vascular intervention medical device company, announced major regulatory and commercial...
